Literature DB >> 30650407

Probable Etoricoxib-Induced Severe Thrombocytopenia: A Case Report.

Guerino Recinella1, Alessandro De Marchi2, Enrico Pirazzoli2, Giampaolo Bianchi2.   

Abstract

OBJECTIVE: To describe a case of likely etoricoxib-induced severe thrombocytopenia. CLINICAL PRESENTATION AND INTERVENTION: A 32-year-old woman was referred to our hospital for disseminated petechial rash after 7 days of therapy with etoricoxib. At admission, the patient's platelet count was 3,000/mm3. At Naranjo's scale correlation between thrombocytopenia and drug was considered as "probable." With the diagnostic tests performed we did not find other causes of thrombocytopenia. Etoricoxib was discontinued. The patient was treated with intravenous immunoglobulin and corticosteroids with a complete resolution of the thrombocytopenia in a few days.
CONCLUSION: The prevalence of thrombocytopenia induced by etoricoxib should be studied as it may not be very rare.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Etoricoxib; Petechial rash; Thrombocytopenia

Mesh：

Substances：

Year:  2019        PMID： 30650407      PMCID： PMC6639571          DOI： 10.1159/000496975

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN： 1011-7571            Impact factor:   1.927


  9 in total

Review 1.  Etoricoxib.

Authors:  Deborah J Cochrane; Blair Jarvis; Gillian M Keating
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Drug-induced thrombocytopenia: a systematic review of published case reports.

Authors:  J N George; G E Raskob; S R Shah; M A Rizvi; S A Hamilton; S Osborne; T Vondracek
Journal:  Ann Intern Med       Date:  1998-12-01       Impact factor: 25.391

3.  Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy.

Authors:  U Pedersen-Bjergaard; M Andersen; P B Hansen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

Authors:  Thana Turajane; Rungsee Wongbunnak; Tanisa Patcharatrakul; Kaseam Ratansumawong; Yutana Poigampetch; Thawee Songpatanasilp
Journal:  J Med Assoc Thai       Date:  2009-12

Review 6.  Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.

Authors:  James N George; Richard H Aster
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

7.  Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

Authors:  K Gottesdiener; T Schnitzer; C Fisher; B Bockow; J Markenson; A Ko; L DeTora; S Curtis; L Geissler; B J Gertz
Journal:  Rheumatology (Oxford)       Date:  2002-09       Impact factor: 7.580

8.  Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

Authors:  Li-Chia Chen; Darren M Ashcroft
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-07       Impact factor: 2.890

Review 9.  Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.

Authors:  Paola Patrignani; Marta L Capone; Stefania Tacconelli
Journal:  Expert Opin Pharmacother       Date:  2003-02       Impact factor: 3.889
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.